Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 18.64% on an a

Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform

HC Wainwright & Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:COGT) with a B

NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful re

NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful re

On September 1, 2026, Cogent Biosciences, Inc. (the "Company") entered into a Commercial Sup

Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 22.44% on an a

Cogent Biosciences is positioned to commercialize bezuclastinib across three indications, leveraging

Deutsche Bank AG acquired a new stake in shares of Cogent Biosciences, Inc. (NASDAQ: COGT) during th

Handelsbanken Fonder AB acquired a new position in shares of Cogent Biosciences, Inc. (NASDAQ: COGT)

Piper Sandler analyst Christopher Raymond maintains Cogent Biosciences (NASDAQ:COGT) with a Overw

Cogent Biosciences (COGT) witnesses a hammer chart pattern, indicating support found by the stock af

Guggenheim analyst Michael Schmidt maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and rais

Up to $400,000,000COMMON STOCKWe have entered into a Sales Agreement with Guggenheim Securities, LLC

Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.52) per share which beat the analy

On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM

Cogent Biosciences (NASDAQ:COGT) has outperformed the market over the past 5 years by 28.96% on an a

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision the

Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective respons

Cogent Biosciences is positioned to build a niche KIT-mutant franchise, leveraging bezuclastinib acr

We're encouraged by the preclinical data from our next-generation JAK2 program being presented a

-  JAK2 V671F poster presentation showcases potential best-in-class properties, including improved s

-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an upda

Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage

Wedbush analyst David Nierengarten reiterates Cogent Biosciences (NASDAQ:COGT) with a Outperform

NDA acceptance with Priority Review builds upon previous assignment of Breakthrough Therapy Designat

NDA acceptance with Priority Review builds upon previous assignment of Breakthrough Therapy Designat

WALTHAM, Mass. and BOULDER, Colo.

WALTHAM, Mass. and BOULDER, Colo., May 12, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq

HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Bu

Cogent Biosciences (NASDAQ:COGT) reported quarterly losses of $(0.53) per share which beat the analy

- Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal

WALTHAM, Mass. and BOULDER, Colo.

Poster DetailsTitle: Characterization of CGT1263, a KRAS (ON/OFF) inhibitor clinical candidate with

– Updated presentation on Cogent's potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivit

Cogent Biosciences, Inc. maintains a Buy rating as bezuclastinib demonstrates blockbuster potential

Cogent Biosciences (NASDAQ: COGT - Get Free Report) and GT Biopharma (NASDAQ: GTBP - Get Free Report

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision the

FDA accepts Cogent Biosciences' NDA for bezuclastinib in NonAdvSM. PDUFA date set for Dec 30, 20

U.S. stock futures were fluctuating on Tuesday after trimming gains on Monday. Futures of major benc